An estriol-eluting pessary to treat pelvic organ prolapse

Sci Rep. 2022 Nov 21;12(1):20021. doi: 10.1038/s41598-022-23791-9.

Abstract

Pelvic organ prolapse affects up to 50% of parous women. Commonly used treatment options have unwelcome attributes; pessaries can cause erosion and estrogen creams need to be applied frequently, which is inconvenient and difficult to administer. This study involved the development of an estriol-releasing pessary utilising 3D printing molds. We incorporated varying amounts of estriol (1%, 10% and 15%) into the silicone pessary. We optimised the mechanical aspects of the pessary so it had a similar strength to commercially available pessaries. We investigated estriol release from the pessary over 3 months. We explored possible interactions between the drug and polymers via FTIR. The MED-4870 silicone ring with similar mechanical strength to pessaries currently used to treat pelvic organ prolapse. The medical pessaries present a sustained release in simulated vaginal fluid over 3 months. The pessary with 10% estriol delivered the optimal dose at 0.8 mg each week. Mechanical strength of this pessary showed no difference after emersion in simulated vaginal fluid for 3-month, supporting the long-term application. An estriol-loaded pessary was successfully developed to treat pelvic organ prolapse with sustained release of estriol over 3 months. This pessary provides promising potential to treat pelvic organ prolapse and vaginal atrophy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Delayed-Action Preparations
  • Estriol
  • Female
  • Humans
  • Pelvic Organ Prolapse* / therapy
  • Pessaries*
  • Silicones

Substances

  • Delayed-Action Preparations
  • Estriol
  • Silicones